m6A-centered Drug Response Information

General Information of the Drug (ID: M6APDG03895)
Name
OMP-52M51
Status
Phase 1
TTD Drug ID
D0X3YY
Target Gene(s) and Their Upstream m6A Regulator, Together with the Effect of Target Gene(s) in Drug Response
The target genes involved in drug-target interaction (such as drug-metabolizing enzymes, drug transporters and therapeutic targets) and drug-mediated cell death signaling (including modulating DNA damage and repair capacity, escaping from drug-induced apoptosis, autophagy, cellular metabolic reprogramming, oncogenic bypass signaling, cell microenvironment, cell stemness, etc.) could be regulated by m6A regulator(s) and affected their corresponding drug response. You can browse detailed information on drug-related target gene(s) mediated by m6A regulators.
Notch-1 receptor (NOTCH1)
Fat mass and obesity-associated protein (FTO)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary Notch-1 receptor (NOTCH1) is a therapeutic target for OMP-52M51. The Fat mass and obesity-associated protein (FTO) has potential in affecting the response of OMP-52M51 through regulating the expression of Notch-1 receptor (NOTCH1). [1], [2]
Methyltransferase-like 14 (METTL14)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary Notch-1 receptor (NOTCH1) is a therapeutic target for OMP-52M51. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of OMP-52M51 through regulating the expression of Notch-1 receptor (NOTCH1). [2], [3]
Methyltransferase-like 3 (METTL3)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary Notch-1 receptor (NOTCH1) is a therapeutic target for OMP-52M51. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of OMP-52M51 through regulating the expression of Notch-1 receptor (NOTCH1). [2], [4]
YTH domain-containing family protein 2 (YTHDF2)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary Notch-1 receptor (NOTCH1) is a therapeutic target for OMP-52M51. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of OMP-52M51 through regulating the expression of Notch-1 receptor (NOTCH1). [2], [5]
References
Ref 1 The tumor-suppressive effects of alpha-ketoglutarate-dependent dioxygenase FTO via N6-methyladenosine RNA methylation on bladder cancer patients. Bioengineered. 2021 Dec;12(1):5323-5333. doi: 10.1080/21655979.2021.1964893.
Ref 2 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
Ref 3 Mettl14 inhibits bladder TIC self-renewal and bladder tumorigenesis through N(6)-methyladenosine of Notch1. Mol Cancer. 2019 Nov 25;18(1):168. doi: 10.1186/s12943-019-1084-1.
Ref 4 METTL3-mediated m(6)A mRNA modification promotes esophageal cancer initiation and progression via Notch signaling pathway. Mol Ther Nucleic Acids. 2021 Jul 21;26:333-346. doi: 10.1016/j.omtn.2021.07.007. eCollection 2021 Dec 3.
Ref 5 YTHDF2 Suppresses Notch Signaling through Post-transcriptional Regulation on Notch1. Int J Biol Sci. 2021 Aug 28;17(14):3776-3785. doi: 10.7150/ijbs.61573. eCollection 2021.